Patent Description:
Rising incident rates of cancer and challenges like multi-drug resistance and side effects possessed by existing classes of anticancer drugs encourage researchers to develop new compounds with potential anticancer activities and newer modes of action. In this regard, phenotype-based screening of diverse compound collections generated by privileged substructure-based diversity-oriented synthesis (pDOS) is considered one of the prominent approaches in the discovery of novel drug leads. Indeed, pDOS is an attractive technique to synthesize small molecules collections with chemical scaffolds that frequently exist in natural products as well as drugs that can target previously unexploited features of disease-relevant proteins.

<NPL>) relates to an intramolecular diaza-diels-alder protocol which is a diastereoselective and modular one-step synthesis of constrained polycyclic frameworks. <CIT> relates to <NUM>-aryl quinols and analogues thereof as therapeutic agents.

A benzopyran skeleton and analogs thereof constitute the core scaffold of many bioactive natural products and synthetic drugs. For instance, the microglial inhibitor P24A01 and P23C07, a potent antitumor agent, have been discovered using the pDOS approach. Other important examples of biologically significant compounds containing benzopyran as the core skeleton are tephrosin, deguelin, acronycine, <NUM>-HT-<NUM> receptor antagonist, tetrahydrocannabinol, metachromin T, and daleformis. There has been a growing interest in these scaffolds and novel and modular routes to access these scaffolds in a one pot reaction manner with good overall yields are described herein. Additionally, there is a continuous need in the art to identify novel compounds useful in the treatment of disease states.

Disclosed herein are antitumor agents and pharmaceutically acceptable salts thereof, processes for the manufacture of these constrained polycyclic benzopyran frameworks, and medicaments containing such compounds. The disclosed polycyclic benzopyrans may have a general formula of A or B:
<CHM>.

The compounds disclosed herein may have anticancer activity, which results in inhibition of tumor cell proliferation, induction of apoptosis, as well as DNA damage. Described below in detail is the use of such compounds in relation to key enzymes, such as thioredoxin reductase, transketolase, cytosol aminopeptidase, glutathione reductase, inositol-<NUM>-phosphate synthase, and/or transferrin receptor proteins.

In one aspect, the present invention provides compounds for use in the treatment of cell proliferative diseases, wherein the compound is a compound having general formula A as well as pharmaceutically acceptable salts thereof.

In general formula A:
<CHM>
is an aryl, heteroaryl, alicyclic, or heteroalicyclic ring, which may be unsubstituted or substituted with <NUM>, <NUM>, <NUM>, or <NUM> substituents independently selected from the group consisting of: a halogen atom, CN, R<NUM>, OR<NUM>, SR<NUM>, N(R<NUM>)<NUM>, C(O)R<NUM>, C(O)OR<NUM>, NR<NUM>C(O)R<NUM>, C(O)NR<NUM>, SO<NUM>R<NUM>, NR<NUM>SO<NUM>R<NUM>, and SO<NUM>N(R<NUM>)<NUM>;.

In another aspect, the present invention provides compounds for use in the treatment of cell proliferative diseases, wherein the compounds are compounds having the general formula B, along with pharmaceutically acceptable salts thereof.

In general formula B:
<CHM>
is an aryl, heteroaryl, alicyclic, or heteroalicyclic ring, which may be unsubstituted or substituted with <NUM>, <NUM>, <NUM>, or <NUM> substituents that may independently be selected from the group consisting of: a halogen atom, CN, R<NUM>, OR<NUM>, SR<NUM>, N(R<NUM>)<NUM>, C(O)R<NUM>, C(O)OR<NUM>, NR<NUM>C(O)R<NUM>, C(O)NR<NUM>, SO<NUM>R<NUM>, NR<NUM>SO<NUM>R<NUM>, and SO<NUM>N(R<NUM>)<NUM>, wherein:.

Disclosed herein are synthetic methods for the preparation of compounds of the general formula A and B and pharmaceutical compositions thereof. Compounds of general formula A can be prepared according to any of the techniques described below in addition to other techniques. For example, a condensation reaction may be followed by an intramolecular Diels-Alder reaction between the compounds of general formula I and II to yield compounds of general formula A.

In general formulas I and II,
<CHM>
, X, R<NUM> and R<NUM> are as previously described herein.

Compounds of general formula B can be prepared according to any suitable technique. For example, a condensation reaction followed by an intramolecular Diels-Alder reaction between the compounds of general formula III and IV may be used to produce compounds of the general formula B.

In general formulas III and IV,
<CHM>
X, and
<CHM>
are as previously described.

Also disclosed herein are pharmaceutical compositions comprising compounds of general formulas A and B.

Also disclosed herein are methods of screening anticancer agents by treating a subject suffering from or susceptible to cancer or a different condition mediated by continuous cell proliferation. The disclosed methods of treatment include, administering to a subject an effective amount of a compound of general formulas A and B or pharmaceutical composition described herein.

Also disclosed herein are methods of analyzing the cell cycle arresting potentials and/or apoptosis in a biological system by administering to a subject or contacting a biological system with an effective amount of one or more compounds of general formulas A and B.

Also disclosed herein is the ability of the compounds of general formulas A and B to disturb cell polymerization dynamics by tubulin formation, which is necessary for cancer cell division.

Also disclosed herein is the potential of the compounds of general formulas A and B to target caspase-<NUM> mediated apoptotic mechanisms present in aggressive forms of breast cancer cells.

Also disclosed herein is a platform capable of disturbing the DNA of cancerous cells and inducing the expression of DNA damage marker proteins in aggressive SKBR-<NUM> cells in an ATR-Chk2 dependent manner.

Also disclosed herein are methods of inhibiting thioredoxin reductase <NUM> (TrxR <NUM>) in a subject or a biological system by administering to the subject or contacting the biological system with an effective amount of one or more compounds of general formulas A and B.

In another aspect, the present invention provides novel compounds according to one of the following chemical structures, including enantiomers and diastereomers thereof:
<CHM>
<CHM>
<CHM>
<CHM>
<CHM>.

In one embodiment, the compounds of the invention are compounds for use in the treatment of a proliferative condition; a condition mediated by thioredoxin/thioredoxin reductase; a condition mediated by transketolase; a condition mediated by cytosol aminopeptidase; a condition mediated by glutathione reductase; a condition mediated by inositol-<NUM>-phosphate synthase; or a condition mediated by transferrin receptors.

In another embodiment, the compounds of the invention are compounds for use in a method of (a) inhibiting cell proliferation; (b) inhibiting cell cycle progression (c) promoting apoptosis; or (d) a combination of one or more of these, in vivo, comprising contacting a cell with one or more of the compounds of the invention.

In yet another embodiment, the compounds of the invention are compounds for use in a method of inhibiting thioredoxin/thioredoxin reductase, or regulating cell proliferation, in vivo, comprising contacting a cell with an effective amount of one or more compounds of the invention.

The invention also provides pharmaceutical compositions comprising one or more of said novel compounds of the invention as an active ingredient.

The invention further provides a method of (a) inhibiting cell proliferation, (b) inhibiting cell cycle progression, (c) promoting apoptosis, or (d) a combination of one or more of these, in vitro, comprising contacting a cell with one or more of said novel compounds of the invention; and
a method of inhibiting thioredoxin/thioredoxin reductase or regulating cell proliferation, in vitro, comprising contacting a cell with an effective amount of one or more of said novel compounds of the invention.

The present invention provides novel heterocyclic fused constrained ring systems, pharmaceutical compositions comprising one or more of said novel heterocyclic fused constrained ring systems, and in vitro uses thereof, as well as compounds of the general formulas A and B for use in the treatment of cell proliferative diseases and pharmaceutically acceptable salts thereof. When discussing such compounds and compositions the following terms have the following meaning unless otherwise indicated.

As used herein, the term "aryl" means an aromatic or partially aromatic hydrocarbon group containing <NUM> to <NUM> carbon atoms and consisting of one or two rings which may be fused to each other or attached to each other via a single bond. Examples of "aryl" groups include phenyl, napthyl, biphenyl, and indenyl groups.

The term "heteroaryl," as used herein, means an aromatic or partially aromatic group consisting of one or two rings, which may be fused to each other or attached to each other via a single bond, and containing <NUM> to <NUM> ring atoms wherein up to four (e.g., one, two, three, or four) ring atoms are heteroatoms and the remaining ring atoms are carbon. Examples of heteroaryl groups include but are not limited to: pyrrolyl, furyl, thienyl, oxazolyl, imidazolyl, purazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furazanyl, indolizinyl, indolyl, isoindolinyl, indazolyl, benzofuryl, benzothienyl, benzimidazolyl, benzthiazolyl, purinyl, quinolizinyl, quinolinyl, isoquinolinyl, isothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, and the like.

The term "alicyclic" means a saturated or unsaturated aliphatic cyclic ring system consisting of one or more rings, which may be fused to each other or attached to each other via a single bond, and containing <NUM> to <NUM> ring atoms, such as carbon atoms. Example alicyclic groups include cyclopentane, cyclohexane, cycloheptane, cyclooctane, and terpene groups.

The term "heteroalicyclic" refers to any five to seven membered monocyclic, saturated, or partially unsaturated ring structure containing at least one heteroatom selected from the group consisting of O, N, and S, optionally containing one to three additional heteroatoms independently selected from the group consisting of O, N, and S, or a nine to ten membered saturated, partially unsaturated, partially aromatic bicyclic or spiro-fused ring system containing at least one heteroatom selected from the group consisting of O, N, and S, and optionally containing one to four additional heteroatoms independently selected from the group consisting of O, N, and S. Examples of heteroalicyclic groups include but are not limited to: pyrrolinyl, pyrrolidinyl, dioxalanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, indolinyl, chromenyl, <NUM>,<NUM>-methylenedioxyphenyl, <NUM>,<NUM>- dihydrobenzofuryl, <NUM>-aza-spiro[<NUM>]decyl, and the like. In some cases, a heterocycloalkyl group may be attached at any heteroatom or carbon atom of a heteroalicyclic ring.

The term "alkyl," as used herein, denotes a saturated, linear, or branched chain hydrocarbon group containing <NUM> to <NUM> carbon atoms, for example <NUM> to <NUM> or <NUM> to <NUM> carbon atoms, such as methyl, ethyl, propyl, isopropyl, l-butyl, <NUM>-butyl, tert-butyl, and the like. Some particular "C1-C8 alkyl" groups have <NUM>, <NUM>, or <NUM> carbon atoms.

The term "halogen" means fluorine, chlorine, bromine, or iodine.

The term "substituted" means a group which may be substituted one to three times by a halogen atom, CN, R<NUM>, OR<NUM>, SR<NUM>, N(R<NUM>)<NUM>, C(O)R<NUM>, C(O)OR<NUM>, NR<NUM>C(O)R<NUM>, C(O)NR<NUM>, SO<NUM>R<NUM>, NR<NUM>SO<NUM>R<NUM>, and/or SO<NUM>N(R<NUM>)<NUM>.

With reference to substituents, the term "independently" means that when more than one of such substituents is possible, such substituents may be the same or different from each other.

The term "pharmaceutically acceptable salt" refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of the disclosed chemical formulas and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Acid-addition salts include, for example, those derived from inorganic acids, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid, and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Base-addition salts include those derived from ammonium, potassium, sodium, and quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide.

The term "polar-aprotic solvent" means a polar solvent which does not contain acidic hydrogen and does not act as a hydrogen bond donor. Examples of polar-aprotic solvents include dimethylsulfoxide, dimethylformamide, hexamethylphosphorotriamide, n-methyl pyrrolidone, tetrahydrofuran, and ACN.

The presently disclosed compounds can possess one or more asymmetric (or chiral) carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The disclosed compounds can be used in the form of pure enantiomers, diastereoisomers, or racemic mixtures. The disclosed isomeric compounds can be utilized as a single isomer or as a mixture of stereochemical isomeric forms. Diastereoisomers, i.e., nonsuperimposable stereochemical isomers, can be separated by conventional means, such as chromatography, distillation, crystallization, or sublimation. Optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base. Examples of appropriate acids include, without limitation, tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid. A mixture of diastereomers can be separated by crystallization followed by liberation of the optically active bases from these salts. An alternative process for separation of optical isomers includes the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers.

Disclosed herein are pro-drugs of the compounds of the invention which may include one or more compounds of the invention and at least one pharmacologically acceptable protecting group which will be removed under physiological conditions, such as, for example, an alkoxy-, aralkyloxy-, acyl- or acyloxy group, such as an ethoxy, benzyloxy, acetyl, or acetyloxy group.

In general, compounds of the formula A and/or B may be administered either individually, or in combination with any other desired therapeutic agent, using known and acceptable methods. Such therapeutically useful agents may be administered, for example, by one of the following routes: orally, for example, in the form of dragees, coated tablets, pills, semi-solid substances, soft or hard capsules, solutions, emulsions, or suspensions; parenterally, for example, in the form of an injectable solution; rectally in the form of suppositories; by inhalation, for example, in the form of a powder formulation or a spray; and/or trans-dermally or intranasally. For the preparation of such tablets, pills, semi-solid substances, coated tablets, dragees, and hard gelatin capsules, the therapeutically usable product may be mixed with pharmacologically inert, inorganic or organic pharmaceutical carrier substances, for example, lactose, sucrose, glucose, gelatin, malt, silica gel, starch, or derivatives thereof, talcum, stearic acid or salts thereof, skimmed milk powder, and/or the like. For the preparation of soft capsules, pharmaceutical carrier substances, such as, for example, vegetable oils, petroleum, animal, or synthetic oils, wax, fat, and polyols may be used. For the preparation of liquid solutions and syrups, pharmaceutical carrier substances, such as, for example, water, alcohols, aqueous saline solution, aqueous dextrose, polyols, glycerol, vegetable oils, petroleum, and animal or synthetic oils may be used. For suppositories, pharmaceutical carrier substances, such as, for example, vegetable oils, petroleum, animal or synthetic oils, wax, fat, and/or polyols may be used. For aerosol formulations, compressed gases that are suitable for this purpose, such as, for example, oxygen, nitrogen, and/or carbon dioxide may be used. The pharmaceutically acceptable agents may also comprise additives for preserving and stabilizing, emulsifiers, sweeteners, flavorings, salts for altering the osmotic pressure, buffers, encapsulation additives, and/or antioxidants.

As used herein with reference to the disclosed compounds, methods of use, and efficacy for treating cancer and related conditions, the following terms have the provided meaning, unless otherwise stated.

The term "anticancer" defines the use of natural/synthetic methods/substances for effective health care to contribute to and/or prevent the uncontrolled proliferation of tumor cells.

The term "breast cancer" refers to a condition that develops in breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple, and/or a red scaly patch of skin.

The term "proliferative" or "proliferation" in biological conditions refers to uncontrolled multiplication due to failure in normal functioning of a system or a cell.

The term "drug" refers to a natural or synthetic substance which (when administered to a living body) affects its functioning or structure, and is used in the diagnosis, mitigation, treatment, prevention of disease, and/or or relief from discomfort.

The term "multi-drug resistance" (MDR) refers to the condition wherein the effect of a drug will be compromised and will not be effective further. MDR may, in some cases, act as a prognostic factor in tumor relapse.

The term "effective amount" when used in connection with a compound of the general formulas A and/or B means an amount of the subject compound effective for treating or preventing cancer or any other related or unrelated disease(s).

The term "full dose-response curve" is used herein with respect to multiple dosages of a compound to determine its response on a biological system, such as a cell-based model, to study the structural and functional relationship of a compound.

The term "microtubule" denotes the microscopic tubular structure present inside the cytoplasm of cells, sometimes aggregating to form more complex structures and eukaryotic cells, maintaining their shape and assisting in forming the cell spindle during cell division.

The term "mitosis" refers to a condition wherein the cell divides in to two daughter cells in an organized manner.

The term "apoptosis" refers to programmed cell death that occurs in multicellular organisms in order to sustain life. Apoptosis often characterized by mainly two forms, extrinsic and intrinsic pathways that lead to cell death process. Conventionally, apoptosis is distinct from necrosis.

The term "mitochondria" refers to an organelle present mainly in eukaryotic organism that is often referred to as the metabolic center for life activities of a cell and provides energy for the cell.

The term "cell cycle" relates to the process of cell division or the series of events that take place in a cell leading to its division and duplication of its DNA to produce two daughter cells.

The term "caspase" includes a set of cysteine-aspartic proteases, cysteine aspartases or cysteine-dependent aspartate-directed proteases, belonging to a family of protease enzymes that play an essential role in programmed cell death (including apoptosis, pyroptosis, and necroptosis) and inflammation.

The term "oncogene" defines a set of genes that are mutated and cause cancer by genetic conformational changes by forming proto-oncogenes.

The term "migration" as used in the present disclosure describes the ability of tumor cells to migrate to different part of the body and accumulate and form multiple types of cancer.

The term "DNA damage" refers to a mechanism by which normal DNA is altered either by endogenous or exogenous factors, thereby initiating a series of events that may ultimately lead to DNA breaks and cell death.

The term "DNA crosslink" refers to a condition wherein various exogenous or endogenous agents react with two nucleotides of DNA, forming a covalent linkage between them and regulating the epigenetic mechanism in humans.

As used herein, the following abbreviations have the following stated meanings:.

The compounds of formulas A and B exhibit broad anticancer activity against multiple cancer cell lines. Thereby, the compounds of formulas A and B can be used in medications for the prevention and/or treatment of a variety of cancers.

The compounds and pharmaceutical compositions described herein may be used in any type of mammalian subject, such as dogs, cats, cows, sheep, horses, and/or humans. The effective amounts of the disclosed compounds may vary according to the particulars of the disease being treated. Effective amounts of the disclosed compounds and pharmaceutical compositions will be readily ascertainable to those skilled in the art upon consideration of the subject disclosure.

The disclosed compounds can be formulated as pharmaceutical compositions and administered to a patient, such as a human patient, in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intra muscular, topical, and/or subcutaneous routes.

The disclosed compounds may be used in combination with one or more other anticancer agents. Suitable anticancer agents include but are not limited to: alkylating agents, nitrogen mustards, folate antagonists, purine antagonists, pyrimidine antagonists, spindle poisons, topoisomerase inhibitors, apoptosis inducing agents, angiogenesis inhibitors, podophyllotoxins, nitrosoureas, protein synthesis inhibitors, kinase inhibitors, antiestrogens, cisplatin, carboplatin, interferon, asparginase, leuprolide, flutamide, megestrol, mitomycin, bleomycin, doxorubicin, Adriamycin, and/or taxol.

The present invention provides novel heterocyclic fused constrained ring systems, pharmaceutical compositions comprising one or more of said novel heterocyclic fused constrained ring systems, and in vitro uses thereof, as well as compounds of general formulas A and B for use in the treatment of cell proliferative diseases and pharmaceutically acceptable salts thereof. The following experimental examples are provided for further clarification and explanation of the disclosed subject matter.

An example process for the preparation of compounds of the general formula A and characterization data for the selected compounds of this class are described in this experimental example.

Procedure i: Aldehyde (general formula I, <NUM> mmol) and <NUM>-aminoazine (general formula II, <NUM> mmol) were mixed in acetonitrile (<NUM>) at room temperature. Then, TFA (<NUM> mmol) was added dropwise and refluxed for <NUM> hours. After completion of the reaction, acetonitrile and excess TFA was removed under vacuum and concentrated to dryness. The crude material was triturated using a mixture of EtOAc and diethyl ether in different ratios to yield pure compounds of general formula A.

Procedure ii: Aldehyde (General formula I, <NUM> mmol) and <NUM>-aminoazine (General formula II, <NUM> mmol) were mixed in <NUM>,<NUM>-dioxane (<NUM>) at room temperature. Then, scandium triflate (<NUM> mol%) was added and continued stirring at room temperature for <NUM> hours. Then, the reaction mixture was heated at <NUM> for <NUM>-<NUM> hours. After completion of the reaction, <NUM>,<NUM>-dioxane was removed under vacuum and concentrated to dryness. The crude material was purified on flash chromatography using EtOAc/hexane or MeOH/DCM as mobile phase gradient to yield pure compounds of general formula A.

Compound 1a was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(Pale yellow solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J= <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O<NUM>S <NUM>, found <NUM> [M+H]+.

Compound 1b was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM>-<NUM> (two s, <NUM>); <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>OS <NUM>, found <NUM> [M+H]+.

Compound 1c was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(Pale yellow solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM>-<NUM> (two s, <NUM>); <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>BrN<NUM>OS <NUM>, found <NUM> [M+H]+.

Compound 1d was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>OS, <NUM>, found <NUM> [M+H]+.

Compound 1e was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(Pale yellow solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM>-<NUM>(m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM> (dd, 1C), <NUM>, <NUM> (dd, 1C), <NUM>-<NUM> (m, 2C), <NUM>, <NUM>, <NUM> (dd, 1C), <NUM>, <NUM>, <NUM> (dd, 1C), <NUM> (dd, 1C), <NUM>, <NUM>, <NUM>, <NUM> (d, 1C), <NUM> (d, 1C), <NUM> (d, 1C); HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>F<NUM>N<NUM>OS <NUM>, found <NUM> [M+H]+.

Compound 1f was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>BrN<NUM>OS, <NUM>, found <NUM> [M+H]+.

Compound <NUM> was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (td, J= <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM>-<NUM> (two s, <NUM>); <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>OS <NUM>, found <NUM> [M+H]+.

Compound <NUM> was prepared following the general reaction procedure ii and had the following chemical structure and characterization data:
<CHM>.

(Orange color solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> - <NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM> Hz, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (q, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>). <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>BrN<NUM>OS <NUM>, found <NUM> [M+H]+.

Compound 1i was prepared following the general reaction procedure ii and had the following chemical structure and characterization data:
<CHM>.

(Orange color solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (q, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (s, <NUM>), <NUM> (two s, <NUM>), <NUM> (t, J = <NUM>, <NUM>). <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J1C-F = <NUM>), <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>FN<NUM>OS <NUM>, found <NUM> [M+H]+.

Compound 1j was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, Acetone) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). <NUM>C NMR (<NUM>, Acetone) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> (2C), <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>OS <NUM>, found <NUM> [M+H]+.

(White solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOD) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM>- <NUM>(m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (dt, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). <NUM>C NMR (<NUM>, MeOD) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> (2C), <NUM>, <NUM>, <NUM>, <NUM>, <NUM> (2C), <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. LCMS (ESI): m/z <NUM> [M+H]+.

(White solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, Acetone) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). MR (<NUM>, Acetone) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>BrN<NUM>OS <NUM>, found <NUM> [M+H]+.

(White solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O<NUM>S <NUM>, found <NUM> [M+H]+.

Compound 1n was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, <NUM>%);<NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (two s, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O<NUM>S <NUM>, found <NUM> [M+H]+.

Compound 1o was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(Off white solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOD) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). <NUM>C NMR (<NUM>, MeOD) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. LCMS (ESI): m/z <NUM> [M+H]+.

Compound 1p was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(Off white solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOD) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (dt, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). <NUM>C NMR (<NUM>, MeOD) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. LCMS (ESI): m/z <NUM> [M+H]+.

Compound 1q was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(Off white solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (dt, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>OS413. <NUM>, found <NUM> [M+H]+.

Compound 1r was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOD) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (dt, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, MeOD) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>BrN<NUM>OS <NUM>, found <NUM> [M+H]+.

(White solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (dt, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>), <NUM> (t, J = <NUM>, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O<NUM>S <NUM>, found <NUM> [M+H]+.

Compound 1t was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dt, J= <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (dt, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>OS <NUM>, found <NUM> [M+H]+.

Compound 1u was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, <NUM>%). <NUM>H NMR (<NUM>, MeOD) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>), <NUM> (dt, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). <NUM>C NMR (<NUM>, MeOD) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. LCMS (ESI): m/z <NUM> [M+H]+.

Compound 1v was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(Off white solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (dt, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>OS <NUM>, found <NUM> [M+H]+.

Compound 1w was prepared following the general reaction procedure i and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, <NUM>%). <NUM>H NMR (<NUM>, MeOD) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). <NUM>C NMR (<NUM>, MeOD) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. LCMS (ESI): m/z <NUM> [M+H]+.

Compound 1x was prepared following the general reaction procedure ii and had the following chemical structure and characterization data:
<CHM>.

(Off white solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> (2C), <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. LCMS (ESI): m/z <NUM> [M+H]+.

Compound 1y was prepared following the general reaction procedure ii and had the following chemical structure and characterization data:
<CHM>.

(Off white solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (t, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>). <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. LCMS (ESI): m/z <NUM> [M+H]+.

Compound 1z was prepared following the general reaction procedure ii and had the following chemical structure and characterization data:
<CHM>.

(Off white solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> - <NUM> (m, <NUM>), <NUM> (s, <NUM>). <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. LCMS (ESI): m/z <NUM> [M+H]+.

In a second experimental example, processes for the preparation of compounds of general formula B and characterization data for the selected compounds are disclosed.

Procedure iii: Aldehyde (general formula III, <NUM> mmol) and <NUM>-aminoazine (general formula IV, <NUM> mmol) were mixed in a polar aprotic solvent (<NUM>) at room temperature. Then, TFA (<NUM> mmol) was added dropwise and refluxed for <NUM> hours. After completion of the reaction, solvent and excess reagent was removed under vacuum and concentrated to dryness. The crude material was triturated using a mixture of EtOAc and diethyl ether in different ratios to yield pure compounds of general formula B.

Procedure iv: Aldehyde (General formula III, <NUM> mmol) and desired <NUM>-aminoazine (General formula II, <NUM> mmol) were mixed in a polar aprotic solvent (<NUM>) at room temperature. Then, TFA (<NUM> mmol) was added dropwise and the reaction mixture was carried out using MW (power <NUM> W, pressure <NUM> psi) at <NUM> to <NUM> for <NUM> mins. After completion of the reaction, solvent and excess reagent was removed under vacuum and concentrated to dryness. The crude material was purified by flash chromatography (DCM:EtOAc) using neutral alumina as a stationary phase to yield pure compounds of general formula B.

Compound 2a was prepared following the general reaction procedure iii and its chemical structure and characterization data is as follows:
<CHM>.

(White solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O <NUM>, found C<NUM>H<NUM>N<NUM>O <NUM> [M]+.

Compound 2b was prepared following the general reaction procedure iii and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O <NUM>, found <NUM> [M]+.

Compound 2c was prepared following the general reaction procedure iii and had the following chemical structure and characterization data:
<CHM>.

(Off white solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O <NUM>, found <NUM> [M]+.

Compound 2d was prepared following the general reaction procedure iii and had the following chemical structure and characterization data:
<CHM>.

(Off white solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O<NUM> <NUM>, found <NUM> [M]+.

Compound 2e was prepared following the general reaction procedure iii and had the following chemical structure and characterization data:
<CHM>.

pale yellow solid (<NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>, <NUM>, found <NUM> [M]+.

Compound 2f was prepared following the general reaction procedure iii and had the following chemical structure and characterization data:
<CHM>.

(Brown solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>, <NUM>, found <NUM> [M]+.

Compound <NUM> was prepared following the general reaction procedure iii and had the following chemical structure and characterization data:
<CHM>.

(Brown solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM> (two s, <NUM>), <NUM> (s, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O<NUM>, <NUM>, found <NUM> [M]+.

(Brown solid, <NUM>, <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>, <NUM>, found <NUM> [M]+.

Compound 2i was prepared following the general reaction procedure iv and had the following chemical structure and characterization data:
<CHM>.

(Off white solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (s, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dt, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O, <NUM>, found <NUM> [M]+.

Compound 2j was prepared following the general reaction procedure iv and had the following chemical structure and characterization data:
<CHM>.

(Pale yellow solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O, <NUM>, found <NUM> [M]+.

Compound <NUM> was prepared following the general reaction procedure iv and had the following chemical structure and characterization data:
<CHM>.

(Brown solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O, <NUM>, found <NUM> [M]+.

(Off white solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM> Hz, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dt, J = <NUM>, <NUM>, <NUM>), <NUM> (s, <NUM>), <NUM>-<NUM> (m, <NUM>) <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>O<NUM>, <NUM>, found <NUM> [M]+.

(White solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, MeOH-d<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (td, J = <NUM>, <NUM>, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (dt, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>); <NUM>C NMR (<NUM>, MeOH-d<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>OS, <NUM>, found <NUM> [M]+.

Compound 2n was prepared following the general reaction procedure iv and had the following chemical structure and characterization data:
<CHM>.

(White solid, <NUM>, yield <NUM>%); <NUM>H NMR (<NUM>, CDCl<NUM>) δ <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (dd, J = <NUM>, <NUM>, <NUM>), <NUM> (t, J = <NUM>, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM> (d, J = <NUM>, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>), <NUM>-<NUM> (m, <NUM>); <NUM>C NMR (<NUM>, CDCl<NUM>) δ <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>; HRMS (ESI-TOF): m/z calcd for C<NUM>H<NUM>N<NUM>OS, <NUM>, found <NUM> [M]+.

In a third experimental example, compounds synthesized in Examples <NUM> and <NUM> were initially screened for their potential anticancer activities against the cancer cell lines DU-<NUM> and MCF7 at a concentration of <NUM>. The results of this screening process are displayed in <FIG> and <FIG>.

The full dose-response curves for the representative compounds on the survival of three cancer cell lines (MCF7, SKBr3, and HCT116) was carried out and the calculated IC<NUM> values are presented in Table <NUM> (below).

In addition, the effect of these compounds on the survival of normal fibroblast strains was studied in comparison to the anticancer drug doxorubicin and the results are shown in <FIG>. These compounds appear to be safe on normal fibroblasts, even at high concentrations (e.g., <NUM>).

In an effort to further understand the mechanism of action of these disclosed compounds, a variety of representative studies were performed on compound 1t.

Cell synchronization and tubulin study: The antiproliferative effect of the compound 1t was tested on MCF7 cells which were synchronized at specific phases of the cell cycle. Cells arrested at G<NUM>/M phase (<NUM>%) of the cell cycle were more sensitive to the compound than asynchronous cells, indicating that the target of this compound is more expressed at this phase of the cell cycle. One way of inhibiting cell proliferation in G<NUM>/M phase is by altering equilibrium between polymerization and depolymerization of microtubule proteins which is required for active mitotic cell division. As evidence, compound 1t showed a strong inhibition to the microtubule formation in comparison to colchicine and taxol which were used as positive controls (see <FIG> and <FIG>).

Apoptosis studies: The molecular effect of compound 1t was evaluated by investigating its apoptotic (<FIG>) and cell cycle arresting potentials (<FIG> and <FIG>). Compound 1t arrests the cells at G<NUM>/G<NUM> phase in MCF-<NUM> cells (><NUM>%) with respect to control cells after <NUM>, <NUM>, <NUM>, and <NUM> hours of treatment. Further, the compound 1t displayed mitochondrial-mediated apoptotic induction with caspase-<NUM> activation even in the aggressive multi-drug resistant breast cancer cells SKBr3.

Pro-apoptotic and anti-apoptotic factors were found to be highly regulated in a concentration dependent manner. For instance, C-Myc oncogenic protein was found to be inhibited with compound 1t in all the tested cell lines. Over-expression of this oncogene could result in tumor cell proliferation and migration and therefore its inhibition may halt tumor growth. Other pro-apoptotic (Bid, Bax, caspase -<NUM> & -<NUM>) and anti-apoptotic (Bcl-xL) proteins were also modulated by compound 1t as evident from western blot analysis and as confirmed by annexin V study (<FIG>). All these results point to compound lt's ability to target multiple cancer cells towards classical cell death process and arrest the cell's turn-over mechanisms.

Other findings that demonstrate the potential therapeutic uses for compound 1t are its effects on the expression of the tumor suppresser gene p53 and its down-stream target, p21. Compound 1t induced up-regulation of p53 in breast cancer cells while its down-stream protein, p21, was found to be overexpressed in HCT116 colon cancer cells. p53 is involved many cellular processes including cell cycle regulation, induction of apoptosis, and DNA repair. Regulating p53 and p21 plays a crucial equilibrium in apoptosis and compound 1t was found to be effective in modulating their expressions.

DNA damage studies: One of the main properties of any efficient chemotherapeutic drug is to induce DNA damage in tumor cells either directly or indirectly by generating harmful DNA crosslinks, which can lead to apoptosis and impact the cell by disrupting gene function and/or impairing transcription, DNA replication, and cell proliferation. To gain additional knowledge of compound 1t's anticancer properties, its mechanism of action to induce DNA damage was studied in breast and colon cancer cells (<FIG>). One of the critical post-translational modifications of chromatin is phosphorylation of multiple proteins involved in DNA damage pathway and one of the earliest events during DNA double strand break is the phosphorylation of Ser139 on the specialized histone called H2AX, which is then referred to as γ-H2AX. Compound 1t induced H2AX phosphorylation in SKBr3 cells after applying its IC<NUM> and Double IC<NUM> treatments.

However, recruitment of phosphatidylinositol-<NUM>-kinase (PI3K) family members to the site of DNA damage is the first step of DNA damage response mechanisms and the phosphorylation of ataxia telangiectasia-mutated (ATM) or ATM-Rad3-related (ATR) kinases often follows. Treatment with compound 1t phosphorylates ATR and its downstream target p53. Further, compound 1t also showed an elevated levels of checkpoint kinase p-Chk2 expression which co-relates to its potentials to inhibit cell cycle progression. Overall, compound 1t was able to induce DNA damage in an ATR-Chk2 dependent pathway in aggressive breast cancer phenotypes.

The unique properties of compound 1t prompted an in-depth analysis to explore its potential novel targets. In particular, Drug Affinity Response Target Stability (DARTS) proteomic assays were performed in a dose-dependent manner and the compound 1t modulated the functions of the following key enzymes which are upregulated in cancer cells: thioredoxin reductase, transketolase, cytosol aminopeptidase, glutathione reductase, inositol-<NUM>-phosphate synthase, transferrin receptor proteins, and dihydrolipoamide dehydrogenase (see <FIG>, <FIG>, <FIG>, <FIG>, <FIG>, <FIG>, and <FIG>, respectively).

Mammalian thioredoxin reductases (TrxRs) are selenocysteine-containing homodimericflavin enzymes that catalyze the NADPH-dependent reduction of oxidized thioredoxins. Some evidence suggests that increased TrxRs levels may facilitate cancer development due to its growth promoting and apoptosis inhibiting functions. Therefore, inhibiting this enzyme should form the foundation of a novel anticancer lead drug candidate. Many drug companies around the world are trying to design drugs that target this enzyme, however, until now there is no clinical anti-cancer drug that specifically targets TrxR although some drugs have been reported to inhibit TrxR to varying extents. Promisingly, compound 1t exhibited concentration-dependent modulation of TrxR with the highest effect observed at <NUM> (<FIG>). One of the hurdles in developing a successful TrxR inhibitor is its cross reactions with thiols present inside the cells. Unlike other proposed metal complexes and Michael acceptors, compound 1t does not have any appropriate reactive groups (such as selenol or a sulfhydryl group) that can undergo cross reactivity with thiol groups. Moreover, according to many reports, inhibiting excessive TrxR levels will also aid in pathogenesis of Parkinson's disease as well as Alzheimer's disease. On the other hand, increased aminopeptidases are typically observed in many cancer tissues and play a key role in tumor cell proliferation, angiogenesis, and tumor invasiveness by regulating extracellular matrix degradation and cell signaling and recognition. Similar to TrxR <NUM>, compound 1t was also found to targets cytosolic aminopeptidase in a dose-dependent manner.

Similarly, deregulated inositol metabolism has been observed in a number of diseases, including cancer, where inositol modulates different critical pathways in disease progression. Moreover, it is expressed consistently in bipolar disorders and Alzheimer's diseases. Compound 1t has shown a dose-dependent affinity to bind to the active site of this enzyme and regulates its function. Likewise, the role of glutathione reductase is well known in cancer progression and chemoresistance. The equilibrium between the glutathione disulphide ratio is critical not only in cancer progression but also in increased oxidative stress which can lead to other disorders. Hence, regulation of these metabolic enzymes could be accomplished by a complete drug which can overcome the issues in chemotherapy, especially when targeted through receptors like transferrin. Compound 1t displayed higher affinity to transferrin receptors, which can enable it to target cancer cells alone by modulating expression of other key enzymes, which appeared to be up-regulated in tumor cells.

The enzyme transketolase (TKT) was found to be yet another target for the compound 1t activity. As TKT reaction plays a pivotal role in pentose phosphate pathway, inhibition of TKT will suppress the pentose phosphate pathway and interrupt the synthesis of coenzymes, ATP, CoA, NAD(P)+, FAD, RNA, and DNA in cancer cells. The over-expressed TKT is reported in many cancer cells, tissues, and patients, wherein it regulates proliferation and viability. A strategy of silencing TKT has shown significant effect in reducing tumor burden in gastric cancer cells. Recent studies have shown that targeting TKT has clinical relevance in cancer therapy, as it can counteract the effect of oxidative stress, a critical factor in cancer development. The initial DART assay showed a strong affinity for compound 1t on this enzyme in a dose-dependent manner and indicates compound 1t could be used for targeting this enzyme to inhibit cancer development (as shown in <FIG>).

Dihydrolipoamide dehydrogenase (DLD) is a mitochondrial enzyme involved in metabolic process that is encoded by the DLD gene. Not many studies have been done to identify the direct involvement of this enzyme in cancers. However, a deregulated level of DLD may modulate mitochondrial-mediated diseases and may impair normal metabolic processes. Compound 1t also regulates this enzyme and may have an impact on inhibiting the energy required for tumor cell growth and metabolism (see <FIG>). The presently disclosed data is encouraging and indicates compound 1t may potentially be used to target multiple key enzymes that are involved in tumor development and progression.

Unless otherwise stated, the following materials, techniques, and methods were used in the experiments described herein.

Purchased chemical reagents and anhydrous solvents were used without further purification. Solvents for extraction and column chromatography were distilled prior to use. TLC analysis was performed with silica gel plates (<NUM>, <NUM> F254) using iodine and a UV lamp for visualization. <NUM>H and <NUM>C NMR experiments were performed on a <NUM> instrument, respectively. Chemical shifts are reported in parts per million (ppm) downstream from the internal tetramethylsilane standard. Spin multiplicities are described as s (singlet), bs (broad singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), or m (multiplet). Coupling constants are reported in Hertz (Hz). ESI mass spectrometry was performed on a Q-TOF high resolution mass spectrometer or Q-TOF Ultim LC-MS.

Dulbecco's Modified Eagles Medium (DMEM), RPMI <NUM> medium and propidium iodide (PI) were purchased from Sigma Aldrich (Darmstadt, Germany). For western blot, the antibodies; c-Myc, p<NUM>, p<NUM>, Bax, Bid, BclxL, GAPDH, caspase-<NUM>, caspase-<NUM>, p-ATM, p-ATR, p-Chk1, p-Chk2, p-P<NUM>, and p-H2AX along with respective mouse/rabbit secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). FITC Annexin V Apoptosis kit was purchased from BD Biosciences (New Jersey, USA). All other chemicals and solvents used were of standard analytical grade. The stock solutions of SIMR compounds were made in <NUM>% DMSO and working solutions for treatments never exceeded ><NUM>% DMSO. The cell lines were gifted from Radiobiology and Experimental Radio Oncology lab, University Cancer Center, Hamburg University, Hamburg, Germany. F180 and HCT116 cells were cultured in DMEM media while MCF-<NUM> and SKBR3 cells were cultured in RPMI along with <NUM>% FBS and <NUM>% CO<NUM> in a humidified incubator at <NUM>. The cells were grown on polystyrene T-<NUM> (<NUM><NUM>) culture flasks and all the experiments were performed at ~<NUM>% cell confluency.

SRB assay was performed on DU-<NUM> and MCF-<NUM> cells in order to find out the sub-lethal dosage (IC<NUM>) of the synthesized compounds based on reported method with minor modifications. Briefly, 1X10<NUM> cells were seeded in a <NUM>-well plate overnight and were treated with different concentrations of compounds and incubated further for <NUM> hours. The wells which were devoid of any treatment served as controls. After the treatment time, the plates were incubated with <NUM>% trichloroacetic acid (TCA) at <NUM> for <NUM> hour. The cells were then washed, dried and exposed to <NUM>% acetic acid for short period. Two hundred microliters of <NUM> mMtris base solution was then added with <NUM> incubation after drying the plates and the OD was read at <NUM> by using a Multiskan™ GO (Thermo Scientific, USA) microplate Spectrophotometer.

The MCF-<NUM>, SKBR3 and HCT116 total cell lysate were prepared after <NUM> hours of treatment with compound 1t at IC<NUM> and DIC<NUM> doses by using 1X laemmli buffer. Total protein concentration was then estimated for each sample and <NUM>-<NUM>µg of protein lysate were loaded equally on <NUM>% SDS-PAGE gel in order to detect various proteins expression levels. In short, the membrane was incubated with different primary antibodies (as mentioned in above section) (<NUM>:<NUM>) overnight after blocking with <NUM> % non-fat milk solution for <NUM> hour. The membrane was then re-probed with respective mouse/rabbit secondary antibodies (<NUM>:<NUM>) for <NUM>, and later developed by enhanced chemiluminescence (ECL) method by using a Chemidoc MP (BioRad, Germany).

The apoptotic level was measured using a kit method as per supplier's protocol. The MCF-<NUM>, SKBR3, and HCT116 cells (3X10<NUM>) were seeded overnight in a T75 cm<NUM> flask for attaining <NUM>% confluency. The cells were treated with IC50 doses of SIMR1281 along with doxorubicin for <NUM>, <NUM>, and <NUM> hours. The cells were then scrapped off and washed twice with ice cold PBS. 2X10<NUM> cells were counted and re-suspended in <NUM> of binding buffer (1X). 5µL of FITC Annexin V and PI was then added to <NUM>µL of cell suspension and incubated at dark for <NUM>. <NUM>µL of 1X binding buffer was finally added to the cells and analyzed immediately by using by a flow cytometer (BD, Accuri C6).

Cell cycle arresting potentials of compound 1t were analyzed by an already established protocol with minor modifications. In brief, 3X10<NUM> cells of MCF-<NUM>, SKBR3, and HCT116 were seeded and incubated overnight in a T75 cm<NUM> flask before treating with IC<NUM> dose of compound 1t for <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, and <NUM> hours. The cells which were devoid of any treatments served as controls for each group. After respective treatment hours, the cells were washed two times with PBS and fixed with ice cold ethanol (<NUM>%) overnight. The cells were then washed two times with cold PBS and 1X10<NUM> cells were then counted and incubated with <NUM> RNAase (<NUM>µg/mL) for <NUM> at <NUM>. The cell pellet was further added with <NUM>µl of propidium iodide (50µg/ mL) and immediately analyzed by a flow cytometer (BD, Accuri C6).

An immunofluorescence method is used for detecting tubulin polymerization effect of compound 1t. The cells (5x10<NUM>/well) were plated overnight on coverslips on a six well plate and treated with IC<NUM> concentration of compound 1t, taxol and colchicine for <NUM> hours. After treatment, the cells were rinsed twice with PBS, fixed with <NUM>% paraformaldehyde, and permeabilized with <NUM>% Triton X-<NUM>. The cells were then blocked with <NUM>% BSA in PBS for <NUM> hour before further incubation with anti-β-tubulin mouse monoclonal antibody overnight at <NUM> (Cell Signaling, San Francisco, CA). The cells were incubated further with Alexa Fluor® <NUM> secondary antibodies (Abcam, UK), after being washed with PBS for <NUM> hour at dark. The cellular microtubules were observed with a Nikon® Eclipse Ti™ Microscope (Japan).

Tubulin polymerization was measured in vitro using the Tubulin Polymerization Assay kit (Cytoskeleton, Denver, CO). In Brief, <NUM>/mL Porcine Tubulin was dissolved in Buffer <NUM> (<NUM> PIPES, <NUM> MgCl2, <NUM> EGTA pH <NUM>, <NUM> fluorescent reporter, <NUM> GTP, <NUM>% glycerol) to a final concentration of <NUM>/mL. Then tubulin solution was transferred to a pre-warmed <NUM>-well plate that contained test compounds, <NUM> paclitaxel or control buffer. The polymerization of tubulin was monitored as fluorescence at <NUM> for <NUM>, and the reading speed was programmed at <NUM> cycle/min with excitation and emission wavelengths of <NUM> and <NUM>, respectively, using the Varioskan® Flash spectral scanning multimode reader (Thermo Fisher Scientific™).

A549 cells (5x10<NUM>/well) plated on coverslips on <NUM> well plate were treated with indicated concentration of test compounds for <NUM> hours. After treatment, cells were rinsed twice with PBS, fixed with <NUM>% paraformaldehyde, and permeabilized with <NUM>% Triton X-<NUM>. Cells then were blocked with <NUM>% BSA in PBS for <NUM> hour before further incubation with anti-β-tubulin mouse monoclonal antibody overnight at <NUM> (#<NUM>, Cell Signaling, San Francisco, CA). Cells were incubated with Alexa Fluor® <NUM> secondary antibodies (Abcam), after being washed with PBS for <NUM> hour at dark room. Cellular microtubules were observed with an Nikon® Eclipse Ti™ microscope (Japan).

Claim 1:
A compound for use in the treatment of cell proliferative diseases, wherein the compound is a compound having the following general formula A or a pharmaceutically acceptable salt thereof:
<CHM>
wherein:
<CHM>
is an aryl, heteroaryl, alicyclic, or heteroalicyclic ring, which may be unsubstituted or substituted with <NUM>, <NUM>, <NUM>, or <NUM> substituents independently selected from the group consisting of: a halogen atom, CN, R<NUM>, OR<NUM>, SR<NUM>, N(R<NUM>)<NUM>, C(O)R<NUM>, C(O)OR<NUM>, NR<NUM>C(O)R<NUM>, C(O)NR<NUM>, SO<NUM>R<NUM>, NR<NUM>SO<NUM>R<NUM>, and SO<NUM>N(R<NUM>)<NUM>;
X is -O, -NR<NUM>, -NSO<NUM>R<NUM>, -CH<NUM>, -CHR<NUM>, or -C(R<NUM>)<NUM>;
Ha and Hb are each hydrogen atoms;
R<NUM> and R<NUM> are:
each independently selected from the group consisting of: a hydrogen, halogen atom, CN, R<NUM>, OR<NUM>, SR<NUM>, N(R<NUM>)<NUM>, C(O)R<NUM>, C(O)OR<NUM>, NR<NUM>C(O)R<NUM>, C(O)NR<NUM>, SO<NUM>R<NUM>, NR<NUM>SO<NUM>R<NUM>, and SO<NUM>N(R<NUM>)<NUM>; or
connected to form a <NUM> or <NUM> membered ring which is fused to ring D, wherein the <NUM> or <NUM> membered ring is either unsubstituted or substituted with <NUM>, <NUM>, <NUM>, or <NUM> substituents independently selected from the group consisting of: a halogen atom, CN, R<NUM>, OR<NUM>, SR<NUM>, N(R<NUM>)<NUM>, C(O)R<NUM>, C(O)OR<NUM>, NR<NUM>C(O)R<NUM>, C(O)NR<NUM>, SO<NUM>R<NUM>, NR<NUM>SO<NUM>R<NUM>, and SO<NUM>N(R<NUM>)<NUM>;
R<NUM> is independently hydrogen or a substituted group selected from the group consisting of: a C<NUM>-<NUM> aliphatic group; a monocyclic <NUM>-<NUM> membered saturated, partially unsaturated, or aryl ring having <NUM>-<NUM> heteroatoms independently selected from nitrogen, oxygen, or sulfur; or a bicyclic <NUM>-<NUM> membered saturated, partially unsaturated, or aryl ring having <NUM>-<NUM> heteroatoms independently selected from nitrogen, oxygen, or sulfur; and
R<NUM> is hydrogen or an unsubstituted or a substituted alkyl, aryl or heteroaryl group.